Solid Biosciences Inc (NASDAQ:SLDB)’s traded shares stood at 0.49 million during the last session, with the company’s beta value hitting 2.03. At the close of trading, the stock’s price was $3.27, to imply an increase of 0.62% or $0.02 in intraday trading. The SLDB share’s 52-week high remains $15.05, putting it -360.24% down since that peak but still an impressive 7.34% since price per share fell to its 52-week low of $3.03. The company has a valuation of $130.65M, with an average of 0.71 million shares in intraday trading volume over the past 10 days and average of 384.68K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Solid Biosciences Inc (SLDB), translating to a mean rating of 1.09. Of 6 analyst(s) looking at the stock, 0 analyst(s) give SLDB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.72.
Solid Biosciences Inc (NASDAQ:SLDB) trade information
After registering a 0.62% upside in the last session, Solid Biosciences Inc (SLDB) has traded red over the past five days. The 5-day price performance for the stock is -11.14%, and -28.91% over 30 days. With these gigs, the year-to-date price performance is -18.25%. Short interest in Solid Biosciences Inc (NASDAQ:SLDB) saw shorts transact 2.06 million shares and set a 6.19 days time to cover.
The extremes give us $12 and $20 for target low and target high price respectively. As such, SLDB has been trading -511.62% off suggested target high and -266.97% from its likely low.
Solid Biosciences Inc (SLDB) estimates and forecasts
Looking at statistics comparing Solid Biosciences Inc share performance against respective industry, we note that the company has outperformed competitors. Solid Biosciences Inc (SLDB) shares are -58.08% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.20% against 16.60%.
SLDB Dividends
Solid Biosciences Inc has its next earnings report out in February. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Solid Biosciences Inc (NASDAQ:SLDB)’s Major holders
Solid Biosciences Inc insiders hold 0.85% of total outstanding shares, with institutional holders owning 90.12% of the shares at 90.90% float percentage. In total, 90.12% institutions holds shares in the company, led by PARALLEL ADVISORS, LLC. As of 2024-06-30, the company held over 7.0 shares.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Solid Biosciences Inc (SLDB) shares. Going by data provided on Sep 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 854.68 shares. This is just over 2.14% of the total shares, with a market valuation of $2.79 million. Data from the same date shows that the other fund manager holds a little less at 599.43, or 1.50% of the shares, all valued at about 1.96 million.
